June 19, 2025

Is More Fiber the Heart’s Ally?

A long-term U.S. study found that greater adherence to a plant-based cholesterol-lowering diet was linked to lower cardiovascular, coronary heart disease, and all-cause mortality.

Conexiant

June 18, 2025

SGLT2 Inhibitor Empagliflozin Preserves Kidney Function After Heart Attack

A secondary analysis of the EMPACT-MI trial, published in Nature Cardiovascular Research, shows that the sodium-glucose cotransporter-2 (SGLT2) inhibitor empagliflozin stabilizes kidney function and reduces heart failure hospitalizations in patients who have recently experienced a heart attack.

Conexiant

June 18, 2025

Weight Loss Showdown: Pills or Scalpel?

A large analysis presented at the ASMBS Annual Meeting found bariatric surgery led to greater long-term weight loss than GLP-1 medications semaglutide and tirzepatide over three years.

Conexiant

June 17, 2025

Global Study Maps Sex Differences in Care

A global study found sex differences in risk factors, care access, and mortality for hypertension, diabetes, and HIV, using comprehensive international datasets.

Conexiant

June 17, 2025

Is Stroke Risk Lower with Semaglutide?

Semaglutide lowered stroke risk compared to empagliflozin in adults with type 2 diabetes, though overall mortality and heart attack rates were similar between the two drugs.

Conexiant

June 16, 2025

Can One Drug Decode Obesity’s Roots?

A new treatment for rare, extreme hunger offers life-changing relief and uncovers clues to obesity’s tangled biology—reshaping how we understand and treat the condition.

KFF Health News

June 16, 2025

Can Gout Therapy Protect Hearts Too?

New research shows achieving serum urate targets within1 year may significantly reduce major cardiovascular events in gout patients.

Conexiant

June 13, 2025

RSV Vaccine Approved for Younger Adults

The FDA has approved Moderna’s mRESVIA vaccine for adults aged 18 to 59 who are at increased risk for RSV, expanding its indication beyond older adults.

Conexiant

June 13, 2025

Overall Survival Benefit Achieved With Inavolisib Plus Palbociclib and Fulvestrant in Advanced Breast Cancer

With a median follow-up of almost 3 years, an overall survival benefit has now been observed with the addition of the PI3K inhibitor inavolisib to the CDK4/6 inhibitor palbociclib and the estrogen rec...

The ASCO Post